white → pink1 → pink1 → red1
1P-LSD
1-Propionyl-d-lysergic acid diethylamide
1P
1P-LSD is a semisynthetic lysergamide psychedelic and LSD prodrug1, distinguished by a propionyl group on the nitrogen of LSD's indole ring2. The compound reached online research-chemical vendors in 2015 after being synthesized as a lawful substitute for LSD.3 Its subjective effects are widely regarded as nearly identical to those of LSD itself.1 It is a structural homologue of ALD-52.4
Dosage & Duration
Dosage
Threshold~15 µg
Light15-50 µg
Moderate50-125 µg
Strong125-200 µg
Heavy200+ µg
Duration
Onset20-60 minutes
Come Up45-120 minutes
Peak3-5 hours
Offset3-5 hours
After Effects6-24 hours
Total8-12 hours
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
In comparison to other psychedelics such as psilocin, LSA and ayahuasca, 1P-LSD is significantly more stimulating and fast paced in terms of the specific style of thought stream produced and contains a large number of potential effects.
Current mind state enhancementThought accelerationNovelty enhancementTime distortionAnalysis enhancementPersonal bias suppressionConceptual thinkingMemory suppressionThought loopsFeelings of interdependent oppositesDelusionsUnity and interconnectednessFeelings of self-designSpirituality enhancementDelineation of thought
Visual
Distortions
Geometry
The visual geometry of 1P-LSD can be described as more similar in appearance to that of 2C-B or 2C-I than psilocin, LSA or DMT. It can be comprehensively described as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, non-immersive in depth and consistent in intensity. At higher dosages, this substance is Level 8A dominant but is also capable of inducing 8B geometry under the right circumstances.
Hallucinatory States
1P-LSD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.
Auditory
Pharmacology
Pharmacodynamics
1P-LSD is believed to function primarily as a prodrug for LSD, with its psychedelic effects thought to result from LSD activity at serotonin 5-HT2A receptors following hydrolysis of the propionyl group.52 Based on structural similarity to LSD, 1P-LSD itself likely acts as a partial agonist at the 5-HT2A receptor, though it displays only 38% the potency of LSD in mouse models.5 It has been proposed that 1P-LSD may also interact with dopamine and norepinephrine receptors, but no experimental data currently supports this. Whether 1P-LSD possesses meaningful intrinsic activity independent of its conversion to LSD remains uncertain.2
Pharmacokinetics
1P-LSD is rapidly hydrolyzed into LSD in vivo.2 When incubated in human serum or liver cells67, or administered to rats and human subjects, high levels of LSD and relatively low levels of 1P-LSD are quickly detected.21 Following intravenous administration in humans, 1P-LSD is detectable in serum for no longer than four hours, after which it is completely converted to LSD.1 A study in two human volunteers1 found that serum levels of 1P-LSD diminished within the first hour of oral administration while LSD was consistently detected throughout the experiment. The oral bioavailability of LSD following ingestion of 1P-LSD was found to be close to 100%.1
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Full Tolerance
Tolerance develops almost immediately after ingestion, preventing the full effects from being experienced more than once every 4-7 days without significantly increasing the dose.
Baseline Reset
14 days
Half Tolerance
5-7 days
Cross Tolerance
Serotonergic psychedelics8
Harm Potential
Addiction & Dependence
Psychological
Extremely Low1P-LSD is considered non-addictive with low abuse potential. Animal studies with LSD show no self-administration behavior, indicating it lacks the pharmacology to initiate or maintain dependence.9 The desire to use can actually decrease with repeated use, making it largely self-regulating.
Physical
Extremely LowVirtually no withdrawal syndrome has been reported when chronic use of LSD is stopped, and 1P-LSD is assumed to share these properties. No physical dependence develops with use.9
Psychosis Risk
1P-LSD may act as a trigger for those with underlying mental disorders. Individuals with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of supervised medical settings.10 Higher doses increase the risk of adverse psychological reactions10 including anxiety, delusions, and panic attacks.
Seizure Risk
Seizures are rare but have been reported,11 with the likelihood largely extrapolated from LSD use. Risk primarily affects those who are genetically predisposed,11 particularly when accompanied by physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
History & Culture
1P-LSD emerged on the online research chemical market in late 2014 and early 2015,1213 representing the first widely available 1-acylated lysergamide derivative.5 It quickly became one of…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
1P-LSD does not appear in the official international control lists for the 1961 Single Convention, the 1971 Convention on Psychotropic Substances, or the Tables of the 1988 Convention. LSD is separately listed under the 1971 Convention, but that listing does not name 1P-LSD.
By Country
United StatesIllegal (analog/blanket ban)Schedule I analogue
Not explicitly scheduled under the Controlled Substances Act. However, as a prodrug of LSD, possession and sale intended for human consumption may be prosecuted under the Federal Analogue Act, which treats substantially similar compounds as Schedule I substances.80
By state
Across the 50 states, D.C., and the permanent territories, most jurisdictions treat 1P-LSD consistently with federal control; listed entries record independently verified differences in state classification or coverage.
MaineNot scheduledNot listed as a Maine scheduled drug
OregonNot scheduledUnscheduled
AustriaIllegal (analog/blanket ban)NPSG
Neue-Psychoaktive-Substanzen-Gesetz15
Not explicitly scheduled but may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz) as a structural analogue of LSD, making supply for human consumption potentially illegal.
CanadaNot scheduledUnscheduled
1P-LSD is not included in the schedules to Canada's Controlled Drugs and Substances Act. Schedule III lists lysergic acid diethylamide (LSD) and its salts, but does not extend that entry to LSD derivatives or analogues; the Act's schedule-based controlled-substance prohibitions therefore do not apply to 1P-LSD on the basis of its similarity to LSD.
ColombiaRestrictedOtras Sustancias
Colombia lists 1P-LSD under "Otras Sustancias" in the new psychoactive substances section of the technical annex to Resolution 003 of 2022. The resolution defines the listed substances for police application of Law 2000 of 2019: carrying or consuming them, including a personal dose, and facilitating or distributing them are prohibited in the public-space areas around educational institutions delimited by the mayor. The measure is a location-specific police restriction rather than a blanket criminal scheduling provision.
Czech RepublicIllegalSeznam IV
Classified as a controlled substance since January 1, 2014.
EstoniaIllegalNimekiri I
Sotsiaalministri määrus nr 7331
Controlled as a Schedule I substance since June 1, 2017.
FranceIllegalAnnexe IV
Arrêté du 20 mai 202134
Listed as a controlled substance under national drug legislation.34
IrelandRestrictedpsychoactive substance
1P-LSD is subject to Ireland's blanket psychoactive-substances regime when supplied for human consumption. The Criminal Justice (Psychoactive Substances) Act 2010 makes selling, importing, or exporting a psychoactive substance an offence where the person knows or is reckless as to whether it is acquired or supplied for human consumption; sale includes supply, distribution, offering for sale, and possession for those purposes. Conviction may carry a fine and up to 12 months' imprisonment summarily, or a fine and up to 5 years' imprisonment on indictment.
ItalyIllegalTabella I
D.P.R. 309/199046
Classified as a Schedule I controlled substance under Italian drug legislation.47
LatviaIllegal (analog/blanket ban)I saraksts
Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām49
Controlled as a structural analogue of LSD following an amendment to drug scheduling that took effect June 1, 2015. Not explicitly named but covered under analogue provisions.50
NorwayIllegalNarkotikalisten
Forskrift om narkotika52
Classified as a controlled substance since February 14, 2013.52
SingaporeIllegalFirst Schedule
Classified as a Class A controlled substance, carrying severe penalties for possession, trafficking, and distribution.
SpainNot scheduledNo list
1P-LSD is not listed in Annex 1 of the current Spanish psychotropic-substances schedules, which separately list lysergide as “LSD, LSD-25” in List I. The decree’s List I prohibition applies to substances included in that list and does not create a structural-analogue class covering 1P-LSD.
SwitzerlandIllegalVerzeichnis E
Betäubungsmittelverzeichnisverordnung65
Explicitly named under Verzeichnis E of controlled substances since December 2015.
UkraineIllegalСписок № 2
Cabinet of Ministers Resolution No. 770 of 6 May 2000, as amended by Resolution No. 192 of 10 March 2021686970
Ukraine lists 1P-LSD in List No. 2 of Table I, the list of especially dangerous psychotropic substances whose circulation is prohibited. Resolution No. 192 of 10 March 2021 added 1P-LSD (1-propionyl-d-lysergic acid diethylamide) to that list. The statutory framework prohibits circulation of Table I substances except for the limited expert and scientific uses authorized by law.
AustraliaProhibitedCitation needed
Classified as a controlled substance under national drug legislation.
BrazilIllegalF2 prohibited psychotropic
Brazil lists 1P-LSD in List F2, the national list of psychotropic substances whose use is prohibited. The ANVISA update incorporates 1P-LSD into the controlled-substances annex of Portaria SVS/MS No. 344/1998.
ChileIllegalArtículo 1
Decreto Supremo N° 867 de 2007, Ministerio del Interior, que aprueba el Reglamento de la Ley N° 20.0002223
El artículo 1 del Decreto Supremo N° 867 clasifica expresamente 1P-LSD, también denominado 1-propionil-dietilamina del ácido lisérgico, como sustancia o droga estupefaciente o sicotrópica productora de dependencia y capaz de provocar graves efectos tóxicos o daños considerables a la salud. La Ley N° 20.000 sanciona la elaboración, fabricación, transformación, preparación o extracción sin autorización, y aplica las mismas penas al tráfico, incluida la importación, exportación, transporte, adquisición, transferencia, posesión, suministro, guarda o porte sin autorización.
CroatiaIllegalPopis I
Popis droga, psihotropnih tvari i biljaka26
Listed as a prohibited substance under national drug control legislation.27
DenmarkIllegalBilag 1
Bekendtgørelse om euforiserende stoffer30
Explicitly named on the list of controlled substances as of August 25, 2015.
FinlandIllegalLiite
Valtioneuvoston asetus 840/201832
Classified as a controlled substance since November 15, 2018.33
GermanyIllegal (analog/blanket ban)Anlage 1
IsraelIllegalFirst Schedule
1P-LSD (1-propionyl-lysergic acid diethylamide; 1P-LAD) is listed in the First Schedule to Israel’s Dangerous Drugs Ordinance [New Version], 5733-1973. The Ordinance defines a dangerous drug as a substance in that Schedule and prohibits its production, preparation, possession, and use without authorization; the Schedule entry has been in force since 1 April 2018. Israel had previously designated the substance as prohibited from distribution in an emergency declaration published on 13 December 2015.
JapanRestrictedDesignated drug
Designated Substances Order48
Listed as a controlled substance under national drug control laws.
LithuaniaIllegalI sąrašas
Narkotinių ir psichotropinių medžiagų sąrašai51
Explicitly named on the list of controlled substances since September 21, 2015.
PolandIllegalNew psychoactive substance
Regulation of the Minister of Health of 11 March 2021 amending the regulation on lists of psychotropic substances, narcotic drugs and new psychoactive substances5354
1P-LSD is listed in Poland’s register of new psychoactive substances. The national listing subjects the substance to Poland’s statutory controls on new psychoactive substances.
RussiaIllegal (analog/blanket ban)List I
Government Resolution No. 68156
Prohibited since 2017 as a derivative of LSD under national drug control laws.
South KoreaIllegal임시마약류
1P-LSD is designated as a temporary narcotic under the Ministry of Food and Drug Safety's Temporary Narcotics Designation Notice, first published on 1 July 2016. The designation prohibits possession, ownership, use, management, import or export, manufacture, sale, brokering, and receipt, except handling approved by the Minister for official purposes. The official public-data record classifies 1P-LSD as an ergoline temporary narcotic and hallucinogen.
SwedenIllegalFörteckning I
Förordning (1992:1554) om kontroll av narkotika64
Specifically scheduled following its emergence as a designer drug. Prohibition took effect January 26, 2016.
TurkeyIllegalLİSTE
Bazı Maddelerin 2313 Sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun Hükümlerine Tabi Tutulması ile 26/1/2015 Tarihli ve 2015/7238 Sayılı Bakanlar Kurulu Kararında Değişiklik Yapılmasına İlişkin Karar (Karar Sayısı: 2016/8548)6667
Prohibited under national drug control legislation since February 2016.
References
Source Pages
Citations
- Christina Grumann, Kerstin Henkel, Simon D Brandt, Alexander Stratford, Torsten Passie, & Volker Auwärter. (August 2020). Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Testing and Analysis, 12(8), 1144–1153. https://doi.org/10.1002/dta.28211234567
- Adam L Halberstadt, Muhammad Chatha, Adam K Klein, John D McCorvy, Markus R Meyer, Lea Wagmann, Alexander Stratford, & Simon D Brandt. (August 2020). Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Neuropharmacology, 172. https://doi.org/10.1016/j.neuropharm.2019.10785612345
- Why Young Brits Are Taking So Much LSD and Ecstasy. Vice (27 July 2015). https://www.vice.com/en/article/this-is-why-so-many-young-brits-are-taking-so-much-acid-and-ecstasy-892/123
- Shu-Hua Zhang, Angeline S Y Tang, Reenie S L Chin, Jia Ying Goh, Mei Ching Ong, Wendy J L Lim, Angeline T W Yap, & Cheuk-Wai So. (May 2023). Stability studies of ALD-52 and its homologue 1P-LSD. J Forensic Sci, 68(3), 1009–1019. https://doi.org/10.1111/1556-4029.152241
- Simon D Brandt, Pierce V Kavanagh, Folker Westphal, Alexander Stratford, Simon P Elliott, Khoa Hoang, Jason Wallach, & Adam L Halberstadt. (September 2016). Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Testing and Analysis, 8(9), 891–902. https://doi.org/10.1002/dta.188412345
- Lea Wagmann, Lilian H J Richter, Tobias Kehl, Franziska Wack, Madeleine Pettersson Bergstrand, Simon D Brandt, Alexander Stratford, Hans H Maurer, & Markus R Meyer. (July 2019). In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem, 411(19), 4751–4763. https://doi.org/10.1007/s00216-018-1558-91
- Christina Grumann, Kerstin Henkel, Alexander Stratford, Maren Hermanns-Clausen, Torsten Passie, Simon D Brandt, & Volker Auwärter. (September 2019). Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. J Pharm Biomed Anal, 174, 270–276. https://doi.org/10.1016/j.jpba.2019.05.0621
- Adam L. Halberstadt. (January 2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99-120. https://doi.org/10.1016/j.bbr.2014.07.0161
- Nichols DE. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.01147812
- Schlag AK, Aday J, Salam I, Neill JC, & Nutt DJ. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 36(3), 258-272. https://doi.org/10.1177/0269881121106910012
- Simonsson O, Goldberg SB, Chambers R, Osika W, Long DM, & Hendricks PS. (2022). Prevalence and associations of classic psychedelic-related seizures in a population-based sample. Drug and Alcohol Dependence, 239, 109586. https://doi.org/10.1016/j.drugalcdep.2022.10958612
- Newer Unregulated Drugs. KFx (April 2015). http://www.kfx.org.uk/resources/NUDlistapr2015.pdf1
- EMCDDA–Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA (list of new psychoactive substances notified for the first time to the EU Early Warning System in 2015). (2015). https://isomerdesign.com/bitnest/external/EMCDDA/New-Drugs-In-Europe-20151
- Future Synthetic Drugs of Abuse. (1988). https://www.erowid.org/library/books_online/future_synthetic/future_synthetic.shtml12
- Neue-Psychoaktive-Substanzen-Gesetz. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=200092951
- ANVISA RDC No. 598 of 9 February 2022, updating Annex I to Portaria SVS/MS No. 344/1998. gov.br (n.d.). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias1
- ANVISA RDC No. 598 of 9 February 2022, updating Annex I to Portaria SVS/MS No. 344/1998. gov.br (n.d.). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/RDC9992025.pdf1
- Controlled Drugs and Substances Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-11.html1
- Controlled Drugs and Substances Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-1.html1
- Controlled Drugs and Substances Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/fra/lois/C-38.8/page-12.html1
- Controlled Drugs and Substances Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html1
- Decreto Supremo N° 867 de 2007, Ministerio del Interior, que aprueba el Reglamento de la Ley N° 20.000. nuevo.leychile.cl (n.d.). https://nuevo.leychile.cl/servicios/Consulta/Exportar?exportar_con_notas_al_pie=True&exportar_con_notas_bcn=True&exportar_con_notas_originales=True&exportar_formato=pdf&hddResultadoExportar=269323.2023-09-16.0.0%23&nombrearchivo=Decreto-867_19-FEB-2008&radioExportar=Normas1
- Decreto Supremo N° 867 de 2007, Ministerio del Interior, que aprueba el Reglamento de la Ley N° 20.000. nuevo.leychile.cl (n.d.). https://nuevo.leychile.cl/servicios/Consulta/Exportar?exportar_con_notas_al_pie=True&exportar_con_notas_bcn=True&exportar_con_notas_originales=True&exportar_formato=pdf&hddResultadoExportar=235507.2024-09-04.0.0%23&nombrearchivo=Ley-20000_16-FEB-2005&radioExportar=Normas1
- Resolución 003 de 2022 del Consejo Nacional de Estupefacientes. minjusticia.gov.co (n.d.). https://www.minjusticia.gov.co/normatividad-co/Resoluciones/Resoluci%C3%B3n%20No.%200003%20de%2002%20de%20agosto%20de%202022.pdf1
- Resolución 003 de 2022 del Consejo Nacional de Estupefacientes. alcaldiabogota.gov.co (n.d.). https://www.alcaldiabogota.gov.co/sisjur/normas/Norma1.jsp?dt=S&i=1298601
- Popis droga, psihotropnih tvari i biljaka. narodne-novine.nn.hr (n.d.). https://narodne-novine.nn.hr/clanci/sluzbeni/2023_02_19_331.html1
- Popis droga, psihotropnih tvari i biljaka iz kojih se može dobiti droga te tvari koje se mogu uporabiti za izradu droga. narodne-novine.nn.hr (n.d.). https://narodne-novine.nn.hr/clanci/sluzbeni/2019_02_13_259.html1
- Nařízení vlády č. 463/2013 Sb.. aplikace.mvcr.cz (n.d.). https://aplikace.mvcr.cz/sbirka-zakonu/ViewFile.aspx?type=c&id=67251
- Nařízení vlády č. 463/2013 Sb. Nařízení vlády o seznamech návykových látek. Zákony pro lidi (n.d.). https://www.zakonyprolidi.cz/cs/2013-4631
- Bekendtgørelse om euforiserende stoffer. retsinformation.dk (n.d.). https://www.retsinformation.dk/eli/lta/2024/4571
- Sotsiaalministri määrus nr 73. riigiteataja.ee (n.d.). https://www.riigiteataja.ee/akt/1250420240101
- Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista annetun valtioneuvoston asetuksen liitteen muuttamisesta. (2018). https://www.finlex.fi/fi/laki/alkup/2018/201808401
- Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista annetun valtioneuvoston asetuksen liitteen muuttamisesta (840/2018). Laki.ai (Finnish statute mirror of Suomen säädöskokoelma / Finlex) (2018). https://laki.ai/fi/lainsaadanto/saadoskokoelma/2018/8401
- Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants. www.legifrance.gouv.fr (20 May 2021). https://www.legifrance.gouv.fr/jorf/id/JORFTEXT00004352355412
- Neue-psychoaktive-Stoffe-Gesetz. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
- Neue-psychoaktive-Stoffe-Gesetz. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__2.html1
- Neue-psychoaktive-Stoffe-Gesetz. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
- Anlage 1 NpSG Neue-psychoaktive-Stoffe-Gesetz. buzer.de (n.d.). https://www.buzer.de/Anlage_1_NpSG.htm1
- Änderungen an Neue-psychoaktive-Stoffe-Gesetz (NpSG). buzer.de (n.d.). https://www.buzer.de/gesetz/12250/l.htm1
- § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html1
- Criminal Justice (Psychoactive Substances) Act 2010. irishstatutebook.ie (n.d.). https://www.irishstatutebook.ie/eli/2010/act/22/section/1/enacted/en/html1
- Criminal Justice (Psychoactive Substances) Act 2010. irishstatutebook.ie (n.d.). https://www.irishstatutebook.ie/eli/2010/act/22/section/3/enacted/en/html1
- Criminal Justice (Psychoactive Substances) Act 2010. irishstatutebook.ie (n.d.). https://www.irishstatutebook.ie/eli/2010/act/22/section/20/enacted/en/html1
- Dangerous Drugs Ordinance [New Version], 5733-1973. main.knesset.gov.il (n.d.). https://main.knesset.gov.il/Activity/Legislation/Laws/Pages/LawPrimary.aspx?lawitemid=20009011
- Dangerous Drugs Ordinance [New Version], 5733-1973. gov.il (n.d.). https://www.gov.il/BlobFolder/legalinfo/homarim-13122015/he/files_legislation_homarim_Homarim-13122015.pdf1
- D.P.R. 309/1990. salute.gov.it (n.d.). https://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=1851&area=sostanzeStupefacenti&menu=vuoto1
- Designated Substances Order. mhlw.go.jp (n.d.). https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/oshirase/20160824.html1
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām. likumi.lv (n.d.). https://likumi.lv/ta/id/121086-noteikumi-par-latvija-kontrolejamajam-narkotiskajam-vielam-psihotropajam-vielam-un-prekursoriem1
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem. Latvijas Republikas tiesību akti (n.d.). http://likumi.lv/doc.php?id=1210861
- Narkotinių ir psichotropinių medžiagų sąrašai. e-seimas.lrs.lt (n.d.). https://e-seimas.lrs.lt/rs/actualedition/TAIS.94030/vMKdRczJXI/format/ISO_PDF/1
- 31 Forskrift om narkotika (narkotikaforskriften). Helse- og omsorgsdepartementet (14 February 2013). https://lovdata.no/dokument/SF/forskrift/2013-02-14-19912
- Regulation of the Minister of Health of 11 March 2021 amending the regulation on lists of psychotropic substances, narcotic drugs and new psychoactive substances. gov.pl (n.d.). https://www.gov.pl/web/gis/nowe-regulacje-w-zakresie-nsp1
- Regulation of the Minister of Health of 11 March 2021 amending the regulation on lists of psychotropic substances, narcotic drugs and new psychoactive substances. technical-regulation-information-system.ec.europa.eu (n.d.). https://technical-regulation-information-system.ec.europa.eu/mt/notification/25158/text/D/PL1
- Legea 194/2011 privind combaterea operatiunilor cu produse susceptibile de a avea efecte psihoactive, altele decat cele prevazute de acte normative in vigoare, republicata 2014. www.dreptonline.ro (n.d.). http://www.dreptonline.ro/legislatie/legea_194_2011_combaterea_operatiunilor_produse_susceptibile_efecte_psihoactive.php1
- Government Resolution No. 681. pravo.gov.ru (n.d.). http://pravo.gov.ru/proxy/ips/?docbody=&nd=1020450971
- Misuse of Drugs Act. sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc1-1
- Misuse of Drugs Act. sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/SL-Supp/S792-2019/Published/201911291700001
- MFDS Temporary Narcotics Designation Notice. mfds.go.kr (n.d.). https://www.mfds.go.kr/brd/m_76/view.do?seq=109091
- MFDS Temporary Narcotics Designation Notice. data.go.kr (n.d.). https://www.data.go.kr/data/15148736/fileData.do1
- MFDS Temporary Narcotics Designation Notice. khidi.or.kr (n.d.). https://www.khidi.or.kr/board/view?boardStyle=&categoryId=&continent=&country=&linkId=48771436&maxIndex=&menuId=MENU01872&minIndex=&no1=3036&pageNum=48&rowCnt=10&schText=&schType=0&upDown=01
- Real Decreto 2829/1977, de 6 de octubre. boe.es (n.d.). https://www.boe.es/buscar/act.php?id=BOE-A-1977-271601
- Real Decreto 2829/1977, de 6 de octubre. aemps.gob.es (n.d.). https://www.aemps.gob.es/medicamentos-de-uso-humano/estupefacientes-y-psicotropos/1
- Förordning (1992:1554) om kontroll av narkotika. lagen.nu (n.d.). https://lagen.nu/1992:1554/konsolidering/2025:771
- Betäubungsmittelverzeichnisverordnung. fedlex.admin.ch (n.d.). https://www.fedlex.admin.ch/eli/cc/2011/363/de1
- Bazı Maddelerin 2313 Sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun Hükümlerine Tabi Tutulması ile 26/1/2015 Tarihli ve 2015/7238 Sayılı Bakanlar Kurulu Kararında Değişiklik Yapılmasına İlişkin Karar (Karar Sayısı: 2016/8548). resmigazete.gov.tr (n.d.). https://www.resmigazete.gov.tr/eskiler/2016/03/20160308.pdf1
- Bazı Maddelerin 2313 Sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun Hükümlerine Tabi Tutulması ile 26/1/2015 Tarihli ve 2015/7238 Sayılı Bakanlar Kurulu Kararında Değişiklik Yapılmasına İlişkin Karar (Karar Sayısı: 2016/8548). mevzuat.gov.tr (n.d.). https://www.mevzuat.gov.tr/mevzuatmetin/1.3.2313.pdf1
- Cabinet of Ministers Resolution No. 770 of 6 May 2000, as amended by Resolution No. 192 of 10 March 2021. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/770-2000-%D0%BF/print1
- Cabinet of Ministers Resolution No. 770 of 6 May 2000, as amended by Resolution No. 192 of 10 March 2021. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/192-2021-%D0%BF/print1
- Cabinet of Ministers Resolution No. 770 of 6 May 2000, as amended by Resolution No. 192 of 10 March 2021. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/60/95-%D0%B2%D1%80/print1
- Psychoactive Substances Act 2016, Section 2: Meaning of "psychoactive substance". legislation.gov.uk (UK National Archives) (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/section/212
- Psychoactive Substances Act 2016. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/section/51
- Psychoactive Substances Act 2016. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/section/81
- Psychoactive Substances Act 2016. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/schedule/11
- Psychoactive Substances Act 2016, Section 4: Producing a psychoactive substance. legislation.gov.uk (UK National Archives) (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/section/41
- The Psychoactive Substances Act 2016 (Commencement) Regulations 2016 (SI 2016/553). UK Government (2016). https://www.legislation.gov.uk/uksi/2016/553/made1
- Controlled Substances Act. uscode.house.gov (n.d.). https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section813&num=0&edition=prelim1
- Controlled Substances Act. uscode.house.gov (n.d.). https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section802&num=0&edition=prelim1
- Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026). U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division (January 2026). https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf1
- 21 U.S. Code § 813 - Treatment of controlled substance analogues. Cornell Law School Legal Information Institute (U.S. Code mirror) (n.d.). https://www.law.cornell.edu/uscode/text/21/8131
- 17-A M.R.S. §§ 1101-1102. legislature.maine.gov (n.d.). https://legislature.maine.gov/legis/statutes/17-A/title17-Asec1101.html1
- 17-A M.R.S. §§ 1101-1102. legislature.maine.gov (n.d.). https://legislature.maine.gov/statutes/17-A/title17-Asec1102.html1
- Or. Rev. Stat. §§ 475.005(6), 475.752; Or. Rev. Stat. § 475.908(3) (limited controlled-substance-analog definition for nonconsensual ingestion).. oregonlegislature.gov (n.d.). https://www.oregonlegislature.gov/bills_laws/ors/ors475.html1
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 1P-LSD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
